Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
暂无分享,去创建一个
R. Schilsky | M. Bertagnolli | P. Friedman | W. Frankel | S. Shak | R. Goldberg | A. Venook | M. Lopatin | R. Warren | D. Niedzwiecki | X. Ye | C. Millward | K. Clark-Langone | M. Lee | N. N. Mahmoud
[1] D. Sargent,et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Kerr,et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Kerr,et al. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Labianca,et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. , 2011, Journal of the National Cancer Institute.
[5] R. Kelley,et al. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? , 2011, Clinical colorectal cancer.
[6] Michal Sheffer,et al. Gene Expression following Exposure to Celecoxib in Humans: Pathways of Inflammation and Carcinogenesis Are Activated in Tumors but Not Normal Tissues , 2011, Digestion.
[7] D. Kerr,et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. Watson,et al. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX® Colon Cancer Assay , 2010, BMC Cancer.
[9] J. Watkinson,et al. Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1 , 2010, BMC Medical Genomics.
[10] S. Paik,et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Labianca,et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. de la Chapelle,et al. Clinical relevance of microsatellite instability in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Bertagnolli,et al. Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. , 2010, Cancer research.
[14] M. Bertagnolli,et al. Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.
[15] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[16] M. Choti,et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[17] C. Compton,et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Washington,et al. Lymphovascular Invasion in Colorectal Cancer: An Interobserver Variability Study , 2008, The American journal of surgical pathology.
[19] W. Schiemann,et al. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. , 2008, Carcinogenesis.
[20] A. Reeve,et al. Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer , 2008, British Journal of Cancer.
[21] B. Boman,et al. How dysregulated colonic crypt dynamics cause stem cell overpopulation and initiate colon cancer. , 2008, Cancer research.
[22] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Benson,et al. Adjuvant therapy for stage II colon cancer: prognostic and predictive markers. , 2007, The Journal of the National Comprehensive Cancer Network.
[24] Hans J. Tanke,et al. The Carcinoma–Stromal Ratio of Colon Carcinoma Is an Independent Factor for Survival Compared to Lymph Node Status and Tumor Stage , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[25] Junhua Yang,et al. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. , 2007, Cancer research.
[26] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Loeffler,et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.
[28] T. Vahlberg,et al. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. , 2005, World journal of gastroenterology.
[29] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[30] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[31] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[32] H. Moses,et al. Stromal fibroblasts in cancer initiation and progression , 2004, Nature.
[33] Daniel J Sargent,et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.
[34] S. Larson,et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] D. Berger,et al. Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions. , 2003, Surgery.
[36] Norman Wolmark,et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Roland L. Dunbrack,et al. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. , 2002, Cancer research.
[38] J. Drevs,et al. Contents of Next Issues · Themenvorschau , 2002, Oncology Research and Treatment.
[39] Ennis,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[40] M E Hammond,et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.
[41] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[42] A. Scott,et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] R. Kelley,et al. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[44] R. Gray. Weighted analyses for cohort sampling designs , 2009 .
[45] EevaSalminen,et al. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer , 2005 .
[46] H. Kalthoff,et al. Transforming Growth Factor- (cid:1) (TGF- (cid:1) ) Type I Receptor/ ALK5-dependent Activation of the GADD45 (cid:1) Gene Mediates the Induction of Biglycan Expression by TGF- (cid:1) * , 2022 .